论文部分内容阅读
目的：探讨β-内酰胺酶抑制剂治疗小儿难治性肺炎临床特点及疗效。方法：分析了2013年6月～2014年4月我院收治的88例小儿难治性肺炎患儿的临床资料，随机将患儿分成观察组44例和对照组44例。观察组选用阿莫西林与克拉维酸合成剂治疗，对照组给予头孢哌酮舒巴坦钠治疗，比较两组患儿治疗疗效及临床症状、体征的消失。结果：观察组44例中，显效30例，有效11例，无效3例，治疗总有效率为93.18%，对照组44例中，显效30例，有效10例，无效13例，治疗总有效率为70.45%，观察组治疗总有效率明显高于对照组，两组比较差异有统计学意义（P＜0.05）。观察组患儿平均退热时间及肺部症状平均消失时间均短于对照组，两组比较差异有统计学意义（P＜0.05）。结论：β-内酰胺酶抑制剂治疗小儿难治性肺炎临床疗效较好，值得推广使用。“,”Objective To investigate the beta lactamase inhibitors in the treatment of children with refractory clinical features and treatment of pneumonia. Methods To analyze the clinical data from 2013 June to 2014 April 88 cases of children admitted to our hospital for patients with refractory pneumonia, random patients were divided into observation group 44 cases and control group of 44 cases. The observation group use of amoxicillin and clavulanic acid synthesis treatment, control group was given the treatment efficacy of cefoperazone sodium and sulbactam sodium in treatment, compared two groups of clinical symptoms and signs disappeared. Results In 44 cases of observation group, 30 cases were markedly improved, effective in 11 cases, 3 had no effect, the treatment the total effective rate was 93.18%, control group of 44 cases, 30 cases were markedly effective, effective 10 cases, 13 cases of invalid, treatment the total effective rate was 70.45%, total effective treatment observation group was obviously higher than that of control group, two groups compare difference was statistically significant (P<0.05). Observation group with average defervescence time and average pulmonary symptoms disappear time are shorter than the control group, comparing the two groups was statistically significant difference (P<0.05). Conclusion Beta lactamase inhibitor treatment children refractory pneumonia clinical curative effect is good, is worth promoting.